NUWE · Nuwellis, Inc. · Webcasts, Transcripts & Audio
$3.50
-0.31 (-8.14%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Going-concern doubt
— flagged Nov 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions, including continued operating losses, negative cash flows from operations, an accumulated deficit of $327.7 million, and the need for additional capital to fund ongoing operations and growth initiatives (including the integration of Rendiatech Ltd., an Israeli company (“Rendiatech”) following the Company’s acquisition), raise substantial doubt about the Company’s ability to continue as a going concern for at least twelve months from the date these financial statements are issued. While management’s plans, including recent financing activities, cost discipline initiatives, and contingency measures, are intended to address these conditions, such plans do not alleviate the substantial doubt.”View the 10-Q filed Nov 12, 2026
Market Cap
$2.06M
Shares
540,912
Volume · Nov 20
4835
Avg daily vol (18 sessions)
2.34M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Nuwellis, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Nuwellis, Inc. (NUWE), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-12
Nuwellis, Inc. (NUWE) Q3 2026 Earnings Call
Revenue
$2.21M
▼ 0.2% YoY Diluted EPS
$-5.81
▼ 103.3% YoY Gross margin
69.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-08-13
Nuwellis, Inc. (NUWE) Q2 2026 Earnings Call Transcript
Confident tone
Revenue growth and gross margin
Installed base and console placements
Cardiorenal platform and Clarity Prime
Revenue
$1.97M
▲ 14.1% YoY Diluted EPS
$-239.76
Gross margin
76.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
Nuwellis, Inc. (NUWE) Q1 2026 Earnings Call Transcript
Confident tone
Pediatrics growth
Financial performance
Commercial expansion and sales team
Revenue
$2.40M
▲ 26.2% YoY Diluted EPS
$-689.85
Gross margin
70.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-10
Nuwellis, Inc. (NUWE) Q4 2025 Earnings Call Transcript
Positive tone
Rendiatek Acquisition and Critical Care Growth
International / EU Exit and Rationalization
Strategic Repositioning to Cardiorenal
Revenue
$2.42M*
▲ 4.4% YoY Gross margin
68.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-12
Nuwellis, Inc. (NUWE) Q3 2025 Earnings Call Transcript
Positive tone
Aquadex adoption and commercial momentum
Critical care
Heart failure and hospital-based outpatient therapy
Revenue
$2.22M
▼ 6.3% YoY Diluted EPS
$177.16
▼ 99.2% YoY Gross margin
65.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
Nuwellis, Inc. (NUWE) Q2 2025 Earnings Call Transcript
Positive tone
Outpatient heart failure
Cardiac surgery / critical care
Pediatrics growth
Revenue
$1.73M
▼ 21.4% YoY Diluted EPS
$-19207.71
Gross margin
55.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Nuwellis, Inc. (NUWE) Q1 2025 Earnings Call Transcript
Positive tone
Pediatric Growth
Heart Failure Category
Critical Care Decline
Revenue
$1.90M
▲ 2.5% YoY Diluted EPS
$-9112.95
Gross margin
56.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-11
Nuwellis, Inc. (NUWE) Q4 2024 Earnings Call
Revenue
$2.32M*
▼ 9% YoY Gross margin
58.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Nuwellis, Inc. (NUWE) Q3 2024 Earnings Call Transcript
Positive tone
Clinical Evidence and Publications
Pediatric Growth
CMS Reimbursement Increase
Revenue
$2.37M
▼ 1.9% YoY Diluted EPS
$23067.45
Gross margin
70.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
Nuwellis, Inc. (NUWE) Q2 2024 Earnings Call Transcript
Positive tone
Pediatric business softness
Revenue growth in heart failure and critical care
DaVita pilot slower than expected
Revenue
$2.19M
▲ 5.7% YoY Diluted EPS
$-249423.30
Gross margin
67.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Nuwellis, Inc. (NUWE) Q1 2024 Earnings Call Transcript
Positive tone
Pediatric growth and QUELimmune launch
Consumable utilization trends
Liquidity and financing
Revenue
$1.86M
▲ 1.7% YoY Diluted EPS
$-318975.30
Gross margin
64.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-06
Nuwellis, Inc. (NUWE) Q4 2023 Earnings Call Transcript
Positive tone
Heart Failure and Clinical Evidence
Pediatric Business Growth
Revenue and Financial Results
Revenue
$2.55M*
▲ 9.1% YoY Gross margin
54.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Nuwellis, Inc. (NUWE) Q3 2023 Earnings Call Transcript
Revenue
$2.41M
▲ 16.8% YoY Diluted EPS
$-837062.10
Gross margin
57.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Nuwellis, Inc. (NUWE) Q2 2023 Earnings Call Transcript
Revenue
$2.08M
▼ 6.2% YoY Diluted EPS
$-1688809.50
Gross margin
55.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Nuwellis, Inc. (NUWE) Q1 2023 Earnings Call Transcript
Revenue
$1.83M
▼ 5.2% YoY Diluted EPS
$-2667168.00
Gross margin
58.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Nuwellis, Inc. (NUWE) Q4 2022 Earnings Call Transcript
Revenue
$2.34M*
▲ 42.4% YoY Gross margin
56.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Nuwellis, Inc. (NUWE) Q3 2022 Earnings Call Transcript
Revenue
$2.06M
▲ 11.4% YoY Diluted EPS
$-17003196.00
Gross margin
61.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Nuwellis, Inc. (NUWE) Q2 2022 Earnings Call Transcript
Revenue
$2.21M
▼ 11.8% YoY Diluted EPS
$-18832243.50
Gross margin
48.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Nuwellis, Inc. (NUWE) Q1 2022 Earnings Call Transcript
Revenue
$1.93M
▲ 0.4% YoY Diluted EPS
$-19656472.50
Gross margin
57.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
Nuwellis, Inc. (NUWE) Q4 2021 Earnings Call Transcript
Revenue
$1.64M*
▼ 19.7% YoY Gross margin
54.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Nuwellis, Inc. (NUWE) Q3 2021 Earnings Call Transcript
Revenue
$1.85M
▼ 2.7% YoY Diluted EPS
$-34728750.00
Gross margin
60.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-10
Nuwellis, Inc. (NUWE) Q2 2021 Earnings Call Transcript
Revenue
$2.51M
▲ 34.6% YoY Diluted EPS
$-33339600.00
Gross margin
60.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-11
Nuwellis, Inc. (NUWE) Q1 2021 Earnings Call Transcript
Revenue
$1.92M
▲ 17.7% YoY Diluted EPS
$-75014100.00
Gross margin
50.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-03
Nuwellis, Inc. (NUWE) Q4 2020 Earnings Call Transcript
Revenue
$2.04M*
▲ 49.5% YoY Gross margin
56.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-10
Nuwellis, Inc. (NUWE) Q3 2020 Earnings Call Transcript
Revenue
$1.90M
▲ 52.1% YoY Diluted EPS
$-96314400.00
Gross margin
46.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-04
Nuwellis, Inc. (NUWE) Q2 2020 Earnings Call Transcript
Revenue
$1.86M
▲ 11.1% YoY Diluted EPS
$-143545500.00
Gross margin
64.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-12
Nuwellis, Inc. (NUWE) Q1 2020 Earnings Call Transcript
Revenue
$1.63M
▲ 34.2% YoY Diluted EPS
$-534359700.00
Gross margin
51.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-03
Nuwellis, Inc. (NUWE) Q4 2019 Earnings Call
Revenue
$1.37M*
▼ 8.8% YoY Gross margin
50.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 webcasts
Key facts
CIK
1506492
CUSIP
67113Y884
13F (30d)
15 filings
12 filers
Visit website
Investor relations